FORADIL COMBI - OPTIMAL DECISION TO ACHIEVE THE ASTHMA CONTROL



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Оптимальным базисным лечением бронхиальной астмы среднетяжелого течения в настоящее время является комбинация длительно действующего в2-агониста (ДДБА) и ингаляционного глюкокортикостероида (иГКС). Данная терапия позволяет существенно снизить дозу иГКС при эффективном контроле симптомов заболевания. Форадил Комби - новый подход к комбинированной терапии: проверенные действующие вещества - новые возможности.

About the authors

N I Il'ina

O M Kurbacheva

Email: Kurbacheva@gmail.com

E A Latysheva

N I Ilina

Institute of Immunology

Institute of Immunology

O M Kurbacheva

Institute of Immunology

Institute of Immunology

E A Latysheva

Institute of Immunology

Institute of Immunology

References

  1. Eagan T.M., Brogger J.C., Eide G.E., Bakke P.S. The incidence of adult asthma: a review. Int. J. Tuberc. Lung. Dis. 2005, v. 9 (6), р. 603-612.
  2. Adams P.E., Marano M.A. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat, 1995, No. 10, р. 193.
  3. Хаитов Р.М., Игнатьева Г.А., Сидорович И.Г. Иммунология. Учебник для студентов медицинских вузов. М., «Медицина», 2000, 432 с.
  4. American Thoracic Society. Proceedings ofthe ATS workshop on refractory asthma. Current understanding, recommendations, and unanswered questions. Am. J. Respir. Crit. Care Med. 2000, No. 162, р. 2341-2351.
  5. Haahtela T., Jarvinen M., Kava T. et al. Comparison of a Я2-agonist, ter-butaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N. Engl. J. Med. 1991, v. 325, p. 388-392.
  6. Van Essen-Zandvliet E.E., Hughes M.D., Waalkens H.J. et al. Effects of 22 months of treatment with inhaled cor-ticosteroids and/or в2-agonists on lung function, airway responsive-ness, and symptoms in children with asthma. Am. Rev. Respir. Dis. 1992, v. 146, p. 547-554.
  7. Global Initiative for Asthma. Global strategy for asthma management and prevention. Washington, D.C.: National Heart, Lung, and Blood Institute, 1995. (Publication no. 95-3659.)
  8. Балаболкин И.И., Тюменцева Е.С. Применение ингаляционных глюкокортикостероидов в лечении бронхиальной астмы у детей. Научный центр здоровья детей РАМН, М., Иммунопатология, аллергология, инфектология. 2001, № 3, с. 38-47.
  9. Jeffery P.K., Godfrey W., Adelroth E. et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. Am. Rev. Respir. Dis. 1992, v. 145, p. 890-899.
  10. Bateman E.D., Bousquet J., Braunstein G.L. Is overall asthma controlbeing achieved? A hypotesis-generating study. Eur. Respir. J. 2001, v. 17, p. 589-595.
  11. Белевский А.С. Взгляд на пациента с точки зрения пациента: исследование INSPIRE». Consilium medicum. 2007, т. 9, № 3, с. 21-27.
  12. Mitchel C., Jenkins C., Scicchitano R. et al. Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulmonary pharmacology and Therapeutics 16 (2003), p. 299-306.
  13. Barnes P.J. Clinical outcome of adding long-acting в-agonists to inhaled corticosteroids. Respir. Med. 2001, v 95 (suppl. B), p. 12-16.
  14. Bowler S. Inhaled steroids in asthma. Should the dose be redused? Aus. Eam. Physic. 2002, v. 31 (8), p. 746-748.
  15. Черняк Б.А., Воржева И.И. Агонисты в2-адренергических рецепторов в терапии бронхиальной астмы: вопросы эффективности и безопасности. Сonsillium medicum, 2006, т. 8, №10.
  16. National Institutes of Health, National Heart, Lung and Blood Institute. Global Initiative for asthma: pocket Guide for Asthma Management and Prevention. NHLBI/WHO NIH; 1998. Publication No. 96-36558B.
  17. Sears M.R., Taylor D.R., Print C.G. et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990, v. 336, p. 1391-1396.
  18. Spitzer W.O., Suissa S., Ernst P. et al. The use of b-agonists and the risk of death and near death from asthma. N. Engl. J. Med. 1992, v. 326, p. 501-506.
  19. Drazen J.M., Israel E., Boushey H.A. et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N. Engl. J. Med. 1996, v. 335, p. 841-847.
  20. Pearlman D.S., Chervinsky P., LaForce C. et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N. Engl. J. Med. 1992, v. 327, p. 1420-1425.
  21. Kesten S., Chapman K.R., Broder I. et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am. Rev. Respir. Dis. 1991, v. 144, p. 622-625.
  22. Greening A.P., Ind P.W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994, v. 344, p. 219-224.
  23. Kruse M., Rosenkranz B., Dobson C. et al. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma. Pulm. Pharmacol. Ther. 2005, v. 18 (3), p. 229-234.
  24. Maconochie and J.K. Forster. Dose-response study with high-dose inhaled salmeterol in healthy subjects. J. G. Br. J. Clin. Pharmacol. 1992, v. 33 (3), p. 342-345.
  25. Molimard M., Raherison C., Lignot S. et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. Journal of Aerosol Medicine. 2003, v. 16, No. 3, р. 249-254.
  26. Nora Y.K. Chew, Hak-Kim Chan. In vitro aerosol performance and dose uniformity between the Eoradile aerolizer and the Oxis Turbuhaler. Journal of Aerosol Medicine. 2001, v. 14, No. 4, р. 495-501.
  27. Clark A.R., Hollingworth A.M. The relationships between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implication for in vitro testing. Journal of Aerosol Medicine. 1993, v. 6, р. 99-110.
  28. Механизм воспаления бронхов и легких и противовоспалительная терапия. Под ред. Г.Б. Федосеева. «Нордмед-издат», СПб, 1998, 687 с.
  29. Kaik G. et al. Sequential Flexible Therapy with Formoterol (Foradil®) plus Budesonide (Miflonide®) Versus a Fixed Combination of Salmeterol and Fluticasone (Seretide®) in Asthma Self-management. European Respiratory Journal. 2002, 20, Supplement 38, 388 p.
  30. Meyer T. et al. Depositionsverteilung von Steroiden bei Patienten mit Asthma bronchiale nach Inhalation von Formoterol Pneumologie. 2004, v. 58, p. 16.
  31. Gessner C. et al. Miflonide®/Foradil® via Aerolizer® Compared with Other Anti-Inflammatory and Anti-Obstructive Therapeutik Regimens. Pneumologie. 2003, v. 57, p. 137-143.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 1970



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies